In a new study in mice published on Thursday in Science, researchers showed how skin cells inherit patterns of gene ...
Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms ...
"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox ...
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...
Sonny Hook is undergoing chemotherapy and steroid treatment after being diagnosed with Langerhans cell histiocytosis (LCH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results